A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

NCT05456867 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC, Non-small-cell Lung Carcinoma

Sponsor

AstraZeneca